Nutrasource Establishes Florida-Based International Institute of Cannabis Research
June 25, 2018
LAKE MARY, Florida (June 25, 2018) – Nutrasource Pharmaceutical and Nutraceutical Services announced today the formation of a new clinical research center in Florida, the International Institute of Cannabis Research (IICR), dedicated to global cannabis research. This location will be spearheaded by its Director and Principal Investigator, Dr. Lane Phillips, a practicing medical doctor, Board Certified in Family Practice, and Board Member of the U.S. Cannabis Coalition. The IICR will specialize in the study of medical applications of cannabis, its cannabinoids, and related products for the purposes of claim validation and patient benefit.
The Dr. Phillips Center for Wellness and the Heathrow Urgent Care Facility, medical practices which see over 8,000 patients annually from Central Florida and have a collective database of over 40,000 patients, will house the new facility. This makes it a prime location and one of Nutrasource’s largest clinical sites within its network of over 300 clinical trial sites in the U.S.
“We are delighted to be working with Dr. Phillips and his team given his rising stature in the cannabis field of medical practice and science,” said William Rowe, President and CEO of Nutrasource. “In many ways, the cannabis space is analogous to the omega-3 field of study 15 years ago, an area in which we are viewed as scientific world leaders. The multiple ingredient components, wide medical applications, and product innovation potential mirror the current challenges and opportunities facing the cannabis industry today,” he added.
Dr. Phillips stated, “we are thrilled and honored to be chosen by Nutrasource as an innovator in this field of science and study. In the next few months and years, the body of knowledge in medical applications for the cannabis product category will be monumental, and it is exciting to be on the leading edge of this research through this collaboration.”
The IICR facility will focus on the use of cannabis and its cannabinoids and terpenes for dosing and pharmacokinetic (PK) studies, as well as research in such medical conditions as post-traumatic stress disorder (PTSD), seizures, anxiety, irritable bowel syndrome (IBS), pain management, and the use of cannabidiol (CBD) for opioid withdrawal. The first of the studies is planned for late 2018.
Nutrasource is a full-service contract research organization that helps companies bring products to market with strong science and regulatory confidence. With over 100 employees across four sites in North America and a vertically-integrated service platform, Nutrasource is your one-stop shop for international regulatory, clinical, and product testing solutions for dietary supplements, pharmaceuticals, and everything in between. www.nutrasource.ca
For more information, please contact:
William Rowe, President and CEO, Nutrasource
1-519-341-3360 | firstname.lastname@example.org | Contact Form
Back to News